Headache, Migraine Clinical Trial
Official title:
Ubrogepant Efficacy and Safety in the Treatment of Acute Migraine in Patients Currently Treated With CGRP Monoclonal Antibodies (CGRPmAbs)
This is a prospective open-label randomized study assessing similar endpoints included in the pivotal trial for ubrogepant, which are pain freedom and freedom from the most bothersome symptom at two hours. Patients between 18-75 years old with a one-year history of migraine who experience ≥3 migraine days/month will be screened. This study will include migraine patients treated with or without injectable CGRPmAbs. As was the case in the clinical trials, this will be a single-attack study. Patients will be randomized to treat a single migraine attack with ubrogepant 50mg or 100mg. Patients will record dosing time, most bothersome symptom (nausea, photophobia, or phonophobia - chosen by patient), pain freedom, pain relief, the use of a 2nd dose if required, and adverse reactions. Patients will follow up within 30 days post treatment. Patients will be assessed for adverse events, and the safety data will be compared with the original clinical trial.
The purpose of this study is to examine the safety and efficacy of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality). There are currently very limited data available about the use of CGRP receptor antagonists in this population, resulting in difficulty obtaining prior authorization to use ubrogepant in patients currently treated with CGRPmAbs. Questions remain as to whether these patients, whose CGRP or CGRP receptors are suppressed, will experience the same safety and efficacy results as patients without such suppression by CGRPmAbs. This is a prospective open-label randomized study assessing similar endpoints included in the pivotal trial for ubrogepant, which are pain freedom and freedom from the most bothersome symptom at two hours. Patients between 18-75 years old with a one-year history of migraine who experience ≥3 migraine days/month will be screened. This study will include migraine patients treated with or without injectable CGRPmAbs. As was the case in the clinical trials, this will be a single-attack study. Patients will be randomized to treat a single migraine attack with ubrogepant 50mg or 100mg. Patients will record dosing time, most bothersome symptom (nausea, photophobia, or phonophobia - chosen by patient), pain freedom, pain relief, the use of a 2nd dose if required, and adverse reactions. Patients will follow up within 30 days post treatment. Patients will be assessed for adverse events, and the safety data will be compared with the original clinical trial. Primary Objective: To evaluate the safety and efficacy of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality). Primary Endpoint: - Pain freedom at 2 hours. - Freedom from most bothersome symptom at 2 hours Secondary Objectives: To assess improvements with the addition of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality). Secondary Endpoint: - Pain relief at 2 hours (this is different from pain freedom: moderate to severe pain reduced to mild or no pain) - Percentage of patients with sustained pain relief from 2-24 hours after initial dose - Percentage of patients with sustained pain freedom from 2-24 hours after initial dose - Pain relief at 2 hours after 2nd dose - Percentage of patients with sustained pain relief from 2-24 hours after 2nd dose - Percentage of patients with sustained pain freedom from 2-24 hours after 2nd dose ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04905654 -
Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura
|
N/A | |
Completed |
NCT04111484 -
Adrenomedullin Effect on Migraine Without Patients
|
N/A | |
Recruiting |
NCT04091789 -
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
|
Phase 2 | |
Completed |
NCT03337620 -
Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine
|
Phase 3 | |
Completed |
NCT02259387 -
Adolescents With Migraine: What's Stress Got To Do With It?
|
||
Completed |
NCT05658185 -
Migraine Difficult to Treat: the Importance of Psychological Care in the Chronic Patient
|
N/A | |
Completed |
NCT05001399 -
Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain
|
N/A | |
Completed |
NCT03490500 -
Using the S100B Protein for Emergency Headache Management Care (S100)
|
||
Completed |
NCT03075020 -
Carbon Monoxide Migraine-inducing Effects in Patients With Migraine Without Aura.
|
N/A | |
Recruiting |
NCT03472092 -
Mind and Body Approaches to Pain Reduction in Youth With Migraine
|
Phase 2 | |
Enrolling by invitation |
NCT04976985 -
Osteopathic Manipulative Treatment and Migraine Headaches
|
N/A | |
Active, not recruiting |
NCT04372264 -
Intravenous Paracetamol, Dexketoprofen and Ibuprofen in the Treatment of Acute Migraine Attack Headache
|
Phase 4 | |
Recruiting |
NCT04623203 -
The Prognosis of Migraine and Tension-Type Headache in Children and Adolescents
|
||
Completed |
NCT04577443 -
The Effect of Adenosine on Cranial Hemodynamic, Headache and Migraine Induction Properties.
|
N/A | |
Completed |
NCT03560024 -
The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by Magnetic Resonance Angiography (MRA) on Healthy Volunteers
|
N/A | |
Completed |
NCT03228355 -
Headache Inducing Effect of Cromakalim in Migraine Patients
|
N/A | |
Completed |
NCT02438553 -
Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related Pain
|
N/A | |
Recruiting |
NCT03577548 -
Influence of Main Psychological and Social Factors on Primary Headaches
|
||
Recruiting |
NCT04715685 -
Mind Body Balance for Pediatric Migraine
|
N/A | |
Completed |
NCT05853900 -
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
|
Phase 3 |